Clinical Trials Browser

Phase 1/2 × gilteritinib × 30 days × Clear all

NCT05520567 2026-03-04

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Phase 1/2 Active not recruiting

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute